Novo Nordisk has appointed a new CEO, Maziar Mike Doustdar, and revised its financial estimates for 2023, forecasting a decline in sales.
Raluca Ioana Draghici
Economy
www.shutterstock.com
Always see our news on Google
Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
10:16
October 13, 2026. TV: What was discussed last night on the news channels
10:04
Luca Niculescu: “No one offered me a guarantee that this government would pass”
09:49
Annual inflation rose again in September and reached 6.6%, according to the National Institute of Statistics
09:32
Rumen Radev announces that two ships were hit by drones in the Black Sea/ One may have sunk, while 12 people may have been injured
09:21
ANM announces temperatures lower than normal until the beginning of November
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
